Multiple Myeloma Hub cover image

What are the pros and cons of bispecific antibodies for multiple myeloma?

Multiple Myeloma Hub

CHAPTER

Introduction

Exploring the latest developments in utilizing bi-specific antibodies for Multiple Myeloma treatment as discussed by Dr. Roberto Mina and Professor Andrzej Jakoboviak, highlighting findings from the phase one Majestic trial with Elra Natham up at meetings such as ASCO 2022.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner